PCGF3

PCGF3 is a subunit of a noncanonical PRC1 complex (PCGF3/5-PRC1) that initiates Polycomb-mediated chromatin silencing, most clearly defined during X chromosome inactivation, where it catalyzes chromosome-wide H2AK119 ubiquitylation that in turn signals recruitment of other noncanonical PRC1 complexes and PRC2 to deposit H3K27 methylation (PMID:28596365). Recruitment of PCGF3/5-PRC1 to the inactive X is directed by the RNA-binding protein hnRNPK, which binds the Xist RNA Polycomb Interaction Domain (XR-PID/B-repeat); deleting this element abolishes Polycomb recruitment and silencing, while synthetic tethering of hnRNPK restores it (PMID:29220657). Loss of Pcgf3/5 causes female-specific embryonic lethality and abrogates Xist-mediated repression (PMID:28596365). Beyond this developmental role, nuclear PCGF3 acts in innate immunity as a negative regulator of antiviral responses: upon type I interferon stimulation it is recruited to interferon-stimulated response elements where it precludes STAT1 binding and dampens interferon-stimulated gene expression (PMID:39368978). PCGF3 transcription is controlled at its promoter by TRF2 acting through a G-quadruplex motif (PMID:29589913) and by USF1, whose activity is constrained by miR-210-3p (PMID:34140779).

1. 2017 High

   Established that PCGF3 is a functional initiator of Polycomb silencing rather than a passive complex member, by showing PCGF3/5-PRC1 deposits the H2AK119ub mark that nucleates downstream PRC1/PRC2 recruitment during X inactivation.

   Evidence Pcgf3/5 double knockout with ChIP-seq, RNA-seq, and functional silencing assays in mouse embryos

   PMID:28596365

   Open questions at the time

   • Does not define the catalytic contribution of PCGF3 versus PCGF5 individually
   • Structure of the PCGF3/5-PRC1 complex and its catalytic mechanism not resolved
   • Generality of this initiator role beyond X inactivation not established here
2. 2017 High

   Resolved how PCGF3/5-PRC1 is targeted to chromatin, identifying hnRNPK bound to the Xist XR-PID/B-repeat as the principal recruitment factor and showing tethering of hnRNPK is sufficient to drive Polycomb recruitment.

   Evidence RNA pulldown, CLIP, Xist deletion mapping, synthetic hnRNPK tethering, ATAC-seq and ChIP-seq

   PMID:29220657

   Open questions at the time

   • Direct physical contact between hnRNPK and PCGF3 not biochemically mapped
   • Whether hnRNPK recruits PCGF3/5-PRC1 at non-Xist loci is unknown
3. 2018 Medium

   Addressed how PCGF3 expression is set transcriptionally, showing TRF2 binds the PCGF3 promoter via a G-quadruplex motif and requires both its N- and C-terminal domains to drive promoter activity.

   Evidence G-quadruplex binding assays, luciferase promoter-reporter assays, TRF2 domain-deletion constructs, ChIP

   PMID:29589913

   Open questions at the time

   • No in vivo functional consequence of TRF2-driven PCGF3 expression established
   • Connection to PCGF3's Polycomb or immune functions not made
4. 2021 Medium

   Placed PCGF3 in a cancer-relevant regulatory axis, showing USF1 activates PCGF3 transcription and that miR-210-3p represses USF1 to lower PCGF3, with PCGF3 knockdown phenocopying tumor-suppressive effects in lung cancer.

   Evidence Dual-luciferase reporter, RNA immunoprecipitation, siRNA knockdown, xenograft model

   PMID:34140779

   Open questions at the time

   • Mechanism by which PCGF3 promotes tumor phenotypes not biochemically defined here
   • Single-lab study
5. 2021 Low

   Proposed a downstream effector pathway for PCGF3 in lung cancer, linking it to cell-cycle and motility regulators via PI3K/AKT signaling.

   Evidence siRNA knockdown, Western blot of cyclins/Rho GTPases, migration assays, LY294002 PI3K inhibition

   PMID:33485844

   Open questions at the time

   • Pathway placement rests on pharmacological inhibition without direct biochemical link to PCGF3
   • No demonstration that PCGF3 acts via its Polycomb chromatin function here
6. 2024 Medium

   Defined a chromatin-independent-from-XCI role for nuclear PCGF3 in innate immunity, showing it is recruited to ISRE elements where it blocks STAT1 binding to suppress interferon-stimulated genes.

   Evidence PCGF3 knockdown/knockout in innate immune cells, ChIP at ISREs, STAT1 binding and ISRE reporter assays

   PMID:39368978

   Open questions at the time

   • Whether ISRE recruitment requires the PCGF3/5-PRC1 complex or H2AK119ub is unknown
   • Mechanism of PCGF3 recruitment to ISREs not defined
   • Single-lab study
7. 2024 Low

   Extended the cancer-axis model to HBV-associated HCC, identifying miR-106b-3p as a direct repressor of PCGF3 with knockdown reducing migration/invasion via PI3K/AKT readouts.

   Evidence Dual-luciferase reporter, siRNA knockdown, Western blot for PI3K/AKT, migration/invasion assays

   PMID:39529637

   Open questions at the time

   • PI3K/AKT link based only on downstream protein expression, not direct biochemistry
   • Single-lab study
8. 2024 Low

   Tested the developmental breadth of PCGF3/5-PRC1, finding it contributes only minimally to neural stem cell proliferation and fate compared with canonical PCGF2/4-PRC1.

   Evidence Conditional Pcgf3/5 vs Pcgf2/4 knockout in mouse neocortex NSCs, proliferation/differentiation assays, ChIP-seq (preprint)

   PMID:bio_10.1101_2024.08.07.606990

   Open questions at the time

   • Preprint, single lab, and a largely negative result for PCGF3/5
   • Does not establish whether noncanonical PRC1 has context-specific roles elsewhere in development

• How PCGF3's two documented activities—Polycomb H2AK119ub deposition and ISRE-based STAT1 competition—are mechanistically related, and whether its tumor phenotypes derive from either, remains unresolved.
• No unified model linking chromatin silencing and interferon suppression
• No structural characterization of PCGF3 within its complex
• Direct substrates and recruitment determinants outside Xist not defined